{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:13:58Z","timestamp":1786720438824,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.kint.2017.06.017","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T23:46:05Z","timestamp":1504136765000},"page":"231-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":233,"title":["Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood\u00a0pressure, body weight, and HbA1c reductions with empagliflozin"],"prefix":"10.1016","volume":"93","author":[{"given":"David Z.I.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Tikkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren S.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2017.06.017_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A\u00a0novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.kint.2017.06.017_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.kint.2017.06.017_bib3","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2017.06.017_bib4","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib5","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2017.06.017_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.06.017_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.06.017_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2017.06.017_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2009-1985","article-title":"Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial","volume":"95","author":"Agarwal","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/eje.1.02100","article-title":"Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome","volume":"154","author":"Kim","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2017.06.017_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.diabres.2009.07.004","article-title":"Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients","volume":"86","author":"Kiyici","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2017.06.017_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2017.06.017_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/HJH.0b013e3283613074","article-title":"Aortic stiffness and cardiovascular risk in type 2 diabetes","volume":"31","author":"Mansour","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2017.06.017_bib19","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.2337\/dc13-0506","article-title":"Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study","volume":"36","author":"Cardoso","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/dc12-0850","article-title":"Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes","volume":"36","author":"Theilade","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.atherosclerosis.2012.05.022","article-title":"Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms","volume":"223","author":"Cooper","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2017.06.017_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1479164112443375","article-title":"Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: the role of immune cell activation and insulin resistance","volume":"10","author":"Samaras","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.kint.2017.06.017_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib24","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2017.06.017_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-014-0169-9","article-title":"Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study","volume":"14","author":"Nishimura","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2017.06.017_bib26","doi-asserted-by":"crossref","first-page":"R1101","DOI":"10.1152\/ajpregu.00390.2012","article-title":"Sodium-retaining effect of insulin in diabetes","volume":"303","author":"Brands","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2017.06.017_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib28","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","article-title":"Acute pharmacodynamic effects of empagliflozin with and without diuretics in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2017.06.017_bib29","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of empagliflozin on blood pressure in patients with type 2 diabetes and hypertension by background antihypertensive medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2017.06.017_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1573402111666150530204136","article-title":"Mechanisms of salt-sensitive hypertension","volume":"11","author":"Luzardo","year":"2015","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.kint.2017.06.017_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.06.017_bib32","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2017.06.017_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1081\/CEH-100001194","article-title":"Relationships between salt sensitivity of blood pressure and sympathetic nervous system activity: a short review of evidence","volume":"23","author":"Strazzullo","year":"2001","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.kint.2017.06.017_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/0886022X.2013.866008","article-title":"Salt sensitivity of blood pressure in non-dialysis patients with chronic kidney disease","volume":"36","author":"Meng","year":"2014","journal-title":"Ren Fail"},{"issue":"suppl 1","key":"10.1016\/j.kint.2017.06.017_bib35","first-page":"A265","article-title":"Empagliflozin has no discernable effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight","volume":"63","author":"Jordan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2017.06.017_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2017.06.017_bib37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.06.017_bib38","first-page":"382","article-title":"Effects of antihypertensive therapy on the hemodynamics of hypertension: clinical implications","volume":"8","author":"Lund-Johansen","year":"1986","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2017.06.017_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817304775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817304775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T10:27:58Z","timestamp":1641464878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253817304775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0085253817304775"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.06.017","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood\u00a0pressure, body weight, and HbA1c reductions with empagliflozin","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}